As of Jul 31
| -0.02 / -1.60%|
The 4 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 4.50, with a high estimate of 5.00 and a low estimate of 3.50. The median estimate represents a +265.85% increase from the last price of 1.23.
The current consensus among 4 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.